



ICRA

ICRA Limited

Ref: ICRA/Natco Pharma Limited/30042024/1

Date: April 30, 2024

Mr. S.V.V.N. Apparao
Chief Financial Officer
Natco Pharma Limited
Road No:2, Banjara Hills
Hyderabad - 500 031

Dear Sir,

Re: Surveillance of ICRA-assigned Credit Rating for Rs. 1,150.00 crore Bank Facilities of Natco Pharma Limited

Please refer to the Rating Agreement executed between ICRA Limited ("ICRA") and your company, whereby, ICRA is required to review its ratings, on an annual basis, or as and when the circumstances so warrant. Based on a review of the latest developments, the Rating Committee of ICRA, after due consideration has reaffirmed the long-term rating at **[ICRA]AA** (pronounced ICRA Double A) ("Rating"). The Rating Committee of ICRA, after due consideration has also reaffirmed the short-term rating at **[ICRA]A1+** (pronounced ICRA A one Plus). The outlook on the long-term rating is **Stable**. For Rating definition(s), please refer to ICRA website at www.icra.in.

In any of your publicity material or other document wherever you are using the above Rating(s), it should be stated as **[ICRA]AA (Stable)/[ICRA]A1+**.

The aforesaid Rating(s) will be due for surveillance any time before **April 22, 2025**. However, ICRA reserves the right to review and/or, revise the above Rating(s) at any time on the basis of new information becoming available, or the required information not being available, or other circumstances that ICRA believes could have an impact on the Rating(s). Therefore, request the lenders and Investors to visit ICRA website at www.icra.in for latest Rating(s) of the Company.

The Rating(s) are specific to the terms and conditions of the Bank Facilities as indicated to us by you, and any change in the terms or size of the same would require a review of the Rating(s) by us. In case there is any change in the terms and conditions or the size of the rated Bank Facilities, the same must be brought to our notice before the Bank Facilities is used by you. In the event such changes occur after the Rating(s) have been assigned by us and their use has been confirmed by you, the Rating(s) would be subject to our review, following which there could be a change in the Rating(s) previously assigned. Notwithstanding the foregoing, any increase in the over-all limit of the Bank Facilities from that specified in the first paragraph of this letter would constitute an enhancement that would not be covered by or under the said Rating Agreement.

The Rating(s) assigned must be understood solely as an opinion and should not be treated, or cause to be treated, as recommendation to buy, sell, or hold the rated Bank Facilities availed/issued by your company.

Building No. 8, 2nd Floor, Tower A
DLF Cyber City, Phase II
Gurugram – 122002, Haryana

Tel.: +91.124.4545300
CIN : L74999DL1991PLC042749

Website: www.icra.in
Email: info@icraindia.com
Helpdesk: +91 9354738909

Registered Office: B-710, Statesman House, 148, Barakhamba Road, New Delhi 110001. Tel. :+91.11.23357940-41

RATING • RESEARCH • INFORMATION



ICRA

You are also requested to forthwith inform us about any default or delay in repayment of interest or principal amount of the instrument rated, as above, or any other debt instruments/ borrowing and keep us informed of any other developments which may have a direct or indirect impact on the debt servicing capability of the company including any proposal for re-schedulement or postponement of the repayment programmes of the dues/ debts of the company with any lender(s) / investor(s), or occurrence of any significant development that could impact the ability of the company to raise funds such as restriction imposed by any authority from raising funds through issuance of debt securities through electronic bidding system. Further, you are requested to inform us immediately as and when the borrowing limit for the instrument rated, as above, or as prescribed by the regulatory authority(ies) is exceeded.

We look forward to your communication and assure you of our best services.

With kind regards,

Yours sincerely,

For ICRA Limited

SUPRIO

BANERJEE

Digitally signed by
SUPRIO BANERJEE

Date: 2024.04.30
11:06:08 +05'30'

Suprio Banerjee

Vice President and Sector Head

supriob@icraindia.com



ICRA

Appendix -A

Instrument Details

| Details of Bank Limits Rated by ICRA (Rated on Long-term/short-term Scale) | Amount (Rs. crore) | Rating | Rating Assigned on |
|--|--------------------|---------------------------------|--------------------|
| Fund Based Working Capital Facilities | | | |
| Indian Bank | 100.00 | [ICRA]AA (Stable)/ [ICRA]A1+ | April 23, 2024 |
| State Bank of India | 100.00 | | |
| Citi Bank N.A. | 100.00 | | |
| Axis Bank | 40.00 | | |
| IndusInd Bank | 115.00 | | |
| ICICI Bank | 80.00 | | |
| RBL Bank | 40.00 | | |
| HDFC Bank | 120.00 | | |
| Kotak Mahindra Bank | 110.00 | | |
| Yes Bank | 10.00 | | |
| Federal Bank | 115.00 | | |
| Sub-Total - A | 930.00 | | |
| Non-Fund Based Working Capital Limits | | | |
| Indian Bank | 30.00 | [ICRA]AA (Stable)/ [ICRA]A1+ | April 23, 2024 |
| State Bank of India | 20.00 | | |
| Yes Bank | 9.00 | | |
| Citi Bank N.A. | 20.00 | | |
| Axis Bank | 10.00 | | |
| Kotak Mahindra Bank | 31.00 | | |
| Sub-Total – B | 120.00 | | |
| Unallocated Limits - C | 100.00 | [ICRA]AA (Stable)/ [ICRA]A1+ | April 23, 2024 |
| Total | 1,150.00 | | |



ICRA

ICRA Limited

Ref: ICRA/Natco Pharma Limited/30042024/2

Date: April 30, 2024

Mr. S.V.V.N. Apparao
Chief Financial Officer
Natco Pharma Limited
Road No:2, Banjara Hills
Hyderabad - 500 031

Dear Sir,

Re: Surveillance of ICRA-assigned Credit Rating for Rs. 400.00 crore Commercial Paper (CP) Programme of Natco Pharma Limited

Please refer to the Rating Agreement executed between ICRA Limited ("ICRA") and your company, whereby, ICRA is required to review its ratings, on an annual basis, or as and when the circumstances so warrant. Based on a review of the latest developments, the Rating Committee of ICRA, after due consideration has reaffirmed the short-term rating at **[ICRA]A1+ (pronounced ICRA A one Plus)**. For Rating definition(s), please refer to ICRA website at www.icra.in.

In any of your publicity material or other document wherever you are using the above Rating(s), it should be stated as **[ICRA]A1+**.

The Rating(s) are specific to the terms and conditions of the Commercial Paper Programme as indicated to us by you, and any change in the terms or size of the same would require a review of the Rating(s) by us. In case there is any change in the terms and conditions or the size of the rated Commercial Paper Programme, the same must be brought to our notice before the Commercial Paper Programme is used by you. In the event such changes occur after the Rating(s) have been assigned by us and their use has been confirmed by you, the Rating(s) would be subject to our review, following which there could be a change in the Rating(s) previously assigned. Notwithstanding the foregoing, any increase in the over-all limit of the Commercial Paper Programme from that specified in the first paragraph of this letter would constitute an enhancement that would not be covered by or under the said Rating Agreement.

The Rating(s) assigned must be understood solely as an opinion and should not be treated, or cause to be treated, as recommendation to buy, sell, or hold the rated Commercial Paper Programme availed/issued by your company.

Additionally, we wish to highlight the following with respect to the Rating(s):

- (a) If the instrument rated, as above, is not issued by you within a period of 3 months from the date of this letter, the Rating(s) would need to be revalidated before issuance;
- (b) Once the instrument is issued, the rating is valid throughout the life of the captioned programme (which shall have a maximum maturity of twelve months from the date of the issuance of the instrument).

Building No. 8, 2nd Floor, Tower A
DLF Cyber City, Phase II
Gurugram – 122002, Haryana

Tel.: +91.124.4545300
CIN : L749999DL1991PLC042749

Website: www.icra.in
Email: info@icraindia.com
Helpdesk: +91 9354738909

Registered Office: B-710, Statesman House, 148, Barakhamba Road, New Delhi 110001. Tel. :+91.11.23357940-41

RATING • RESEARCH • INFORMATION



ICRA

The Rating(s), as aforesaid, however, should not be treated as a recommendation to buy, sell or hold CP issued by you. The Rating(s) is restricted to your CP programme size of **Rs. 400.00** crore only. In case, you propose to enhance the size of the CP programme, the same would require to be rated afresh. ICRA does not assume any responsibility on its part, for any liability, that may arise consequent to your not complying with any eligibility criteria, applicable from time to time, for issuance of CP.

You are also requested to forthwith inform us about any default or delay in repayment of interest or principal amount of the instrument rated, as above, or any other debt instruments/ borrowing and keep us informed of any other developments which may have a direct or indirect impact on the debt servicing capability of the company including any proposal for re-schedulement or postponement of the repayment programmes of the dues/ debts of the company with any lender(s) / investor(s), or occurrence of any significant development that could impact the ability of the company to raise funds such as restriction imposed by any authority from raising funds through issuance of debt securities through electronic bidding system. Further, you are requested to inform us immediately as and when the borrowing limit for the instrument rated, as above, or as prescribed by the regulatory authority(ies) is exceeded.

We look forward to your communication and assure you of our best services.

With kind regards,

Yours sincerely,

For ICRA Limited

SUPRIO

BANERJEE

Digitally signed by
SUPRIO BANERJEE

Date: 2024.04.30
11:06:54 +05'30'

Suprio Banerjee

Vice President and Sector Head

supriob@icraindia.com